title: Clinical aspects and management of AIDS-related lymphoma.
abstract: The incidence of non-Hodgkin's lymphoma (NHL) is increased by approximately 100-fold in patients with advanced HIV infection. Clinical presentations may include systemic lymphoma, primary central nervous system (CNS) lymphoma, and primary effusion lymphoma. Systemic lymphoma is the most common presentation, is almost always of intermediate or high-grade histology and B-cell phenotype, and usually involves extranodal sites. The disease is potentially curable with combination chemotherapy used for immunocompetent patients with lymphoma, although cure is achieved in only approximately 10-35% of patients. Primary CNS lymphoma may be difficult to distinguish from cerebral infection. The prognosis is very poor, although approximately 10% of patients selected for therapy may survive beyond 1 year with brain irradiation. Attention to infection prophylaxis and antiretroviral therapy is important. Evidence suggests that highly active antiretroviral therapy (HAART) has resulted in a decreased incidence of lymphoma, and that patients with systemic lymphoma treated in the post-HAART era have a better prognosis.
authors: Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center-Weiler Division, Department of Oncology, 2 South, Room 47-48, 1825 Eastchester Road, Bronx, NY 10461, USA. sparano@jimmy.harvard.edu
authors: J A
authors: JA
authors: Sparano
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000517:prevention & control; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D017326:Clinical Trials, Phase III as Topic; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006410:Hematopoiesis; D006801:Humans; D007262:Infusions, Intravenous; D016483:Lymphoma, AIDS-Related / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D019380:Anti-HIV Agents; D016178:Granulocyte-Macrophage Colony-Stimulating Factor